Hideo Komita

Jikei University School of Medicine

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Sadamu Homma

Jikei University School of Medicine

Shigeo Koido

Jikei University School of Medicine

Hisao Tajiri

Jikei University School of Medicine

Toshifumi Ohkusa

Jikei University Kashiwa hospital

Kan Uchiyama

Jikei University Kashiwa hospital

Masato Okamoto

Tsurumi University

Shin Kan

Jikei University Kashiwa hospital

Jianlin Gong

Boston University

Kazuki Takakura

Jikei University School of Medicine

Shunichi Odahara

Jikei University Kashiwa hospital

Cooperative Institutions

Jikei University School of Medicine

Jikei University Kashiwa hospital

Osaka University

University of Pittsburgh

The University of Tokyo

The Jikei University Hospital

UPMC Hillman Cancer Center

Kitasato University

Weatherford College

Katsushika Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Tu1887 Fusions Cells Generated With Combined TLR2/4-Activated Dendritic Cells and Tumor Cells Induce Efficient Antigen-Specific Cytotoxic T Lymphocytes Through IL-12p70 Production

Gastroenterology (2013)

Kazuki Takakura Shigeo Koido Sadamu Homma Akitaka Takahara Shunichi Odahara

10.1016/s0016-5085(13)63244-8

Cite

Citations (1)

Supplementary Table S2 from Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer

Shigeo Koido Sadamu Homma Masato Okamoto Kazuki Takakura Masako Mori

Clinical efficacy results of patients with pancreatic ductal adenocarcinoma.

10.1158/1078-0432.22456152

Cite

Citations (0)

Supplementary Figure S1 from Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer

Shigeo Koido Sadamu Homma Masato Okamoto Kazuki Takakura Masako Mori

Study profile.

10.1158/1078-0432.22456164.v1

Cite

Citations (0)

Supplementary Figure 3 from CD8+ T-Cell Responses against Hemoglobin-β Prevent Solid Tumor Growth

Hideo Komita Xi Zhao Jennifer L. Taylor Louis J. Sparvero Andrew A. Amoscato

Supplementary Figure 3 from CD8+ T-Cell Responses against Hemoglobin-β Prevent Solid Tumor Growth

Solid tumor

10.1158/0008-5472.22374165.v1

Cite

Citations (0)

Supplementary Figure 1 from CD8+ T-Cell Responses against Hemoglobin-β Prevent Solid Tumor Growth

Hideo Komita Xi Zhao Jennifer L. Taylor Louis J. Sparvero Andrew A. Amoscato

Supplementary Figure 1 from CD8+ T-Cell Responses against Hemoglobin-β Prevent Solid Tumor Growth

Solid tumor

10.1158/0008-5472.22374171

Cite

Citations (0)

Fusions between dendritic cells and whole tumor cells as anticancer vaccines

OncoImmunology (2013)

Shigeo Koido Sadamu Homma Masato Okamoto Yoshihisa Namiki Kazuki Takakura

Various strategies have been developed to deliver tumor-associated antigens (TAAs) to dendritic cells (DCs). Among these, the fusion of DCs and whole cancer cells can process a broad array of TAAs, including hitherto unidentified molecules, and present them in complex with MHC Class I and II molecules and in the context of co-stimulatory signals. DC-cancer cell fusions have been shown to stimulate potent antitumor immune responses in animal models. In early clinical trials, however, the antitumor effects of DC-cancer cell fusions are not as vigorous as in preclinical settings. This mini-review summarizes recent advances in anticancer vaccines based on DC-cancer cell fusions.

10.4161/onci.24437

Cite

Citations (43)

Current Immunotherapeutic Approaches in Pancreatic Cancer

Clinical and Developmental Immunology (2011)

Shigeo Koido Sadamu Homma Akitaka Takahara Yoshihisa Namiki Shintaro Tsukinaga

Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer.

10.1155/2011/267539

Cite

Citations (76)

Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma

Cancer Immunology Immunotherapy (2016)

Yasuharu Akasaki Tetsuro Kikuchi Sadamu Homma Shigeo Koido Toshifumi Ohkusa

Temozolomide

10.1007/s00262-016-1905-7

Cite

Citations (57)

S2013 Fusions of Human Dendritic Cells and Pancreatic Carcinoma Cells Induce Antigen-Specific Antitumor Immune Responses

Gastroenterology (2009)

Shigeo Koido Eiichi Hara Sadamu Homma Hideo Komita Akitaka Takahara

Pancreatic carcinoma

10.1016/s0016-5085(09)61429-3

Cite

Citations (0)

Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines

BioMed Research International (2011)

Shigeo Koido Sadamu Homma Akitaka Takahara Yoshihisa Namiki Hideo Komita

Although dendritic cell (DC)- based cancer vaccines induce effective antitumor activities in murine models, only limited therapeutic results have been obtained in clinical trials. As cancer vaccines induce antitumor activities by eliciting or modifying immune responses in patients with cancer, the Response Evaluation Criteria in Solid Tumors (RECIST) and WHO criteria, designed to detect early effects of cytotoxic chemotherapy in solid tumors, may not provide a complete assessment of cancer vaccines. The problem may, in part, be resolved by carrying out immunologic cellular monitoring, which is one prerequisite for rational development of cancer vaccines. In this review, we will discuss immunologic monitoring of cellular responses for the evaluation of cancer vaccines including fusions of DC and whole tumor cell.

10.1155/2011/910836

Cite

Citations (12)